Vascular endothelial growth factor blockade alters magnetic resonance imaging biomarkers of vascular function and decreases barrier permeability in a rat model of lung cancer brain metastasis

Fluids and Barriers of the CNS

Volumn 12, Issue 1, 2015, Pages

  Pishko, Gregory L ^a   Muldoon, Leslie L ^a   Pagel, Michael A ^b   Schwartz, Daniel L ^a   Neuwelt, Edward A ^a,b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b PORTLAND VA MEDICAL CENTER   (United States)

Author keywords

Anti angiogenic drugs; Bevacizumab; Blood brain barrier; Cerebral blood volume; Drug delivery; Magnetic resonance imaging; Tumor model; Vascular normalization

Indexed keywords

BEVACIZUMAB; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; BIOLOGICAL MARKER;

ANIMAL EXPERIMENT; ANTIANGIOGENIC THERAPY; ARTICLE; BLOOD BRAIN BARRIER; BLOOD VESSEL PERMEABILITY; BLOOD VOLUME; BRAIN METASTASIS; CONTROLLED STUDY; DRUG PENETRATION; GRAY MATTER; HUMAN; LUNG ADENOCARCINOMA; LUNG CANCER; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RAT; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT; WATER CONTENT; ADENOCARCINOMA; ANIMAL; BRAIN; BRAIN NEOPLASMS; CAPILLARY PERMEABILITY; DISEASE MODEL; DRUG EFFECTS; FEMALE; LUNG TUMOR; METABOLISM; NEOVASCULARIZATION, PATHOLOGIC; NUDE RAT; PATHOLOGY; PERMEABILITY; SECONDARY; TREATMENT OUTCOME; TUMOR CELL LINE; VASCULARIZATION;

ADENOCARCINOMA; ANGIOGENESIS INHIBITORS; ANIMALS; BEVACIZUMAB; BIOMARKERS; BRAIN; BRAIN NEOPLASMS; CAPILLARY PERMEABILITY; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; LUNG NEOPLASMS; MAGNETIC RESONANCE IMAGING; NEOVASCULARIZATION, PATHOLOGIC; PERMEABILITY; RATS; RATS, NUDE; TREATMENT OUTCOME;

EID: 84929320945     PISSN: None     EISSN: 20458118     Source Type: Journal    
DOI: 10.1186/2045-8118-12-5     Document Type: Article

References (38)

1. Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai P, Sawaya RE: Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol 2004, 22:2865-72. 10.1200/JCO.2004.12.149
2. Castrucci WA, Knisely JP: An update on the treatment of CNS metastases in small cell lung cancer. Cancer J 2008, 14:138-46. 10.1097/PPO.0b013e318172d6e1
3. Zimmermann S, Dziadziuszko R, Peters S: Indications and limitations of chemotherapy and targeted agents in non-small cell lung cancer brain metastases. Cancer Treatment Rev 2014, 40:716-22. 10.1016/j.ctrv.2014.03.005
4. Huang H, Held-Feindt J, Buhl R, Mehdorn HM, Mentlein R: Expression of VEGF and its receptors in different brain tumors. Neurol Res 2005, 27:371-7. 10.1179/016164105X39833
5. Ferrara N: VEGF as a therapeutic target in cancer. Oncology 2005,69(Suppl. 3):11-6.
6. Holash J, Maisonpierre PC, Compton D, Boland P, Alexander CR, Zagzag D, Yancopoulos GD, Wiegand SJ: Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999, 284:1994-8. 10.1126/science.284.5422.1994
7. Jain RK: Antiangiogenic therapy for cancer: current and emerging concepts. Oncology 2005, 19:7-16.
8. Peak SJ, Levin VA: Role of bevacizumab therapy in the management of glioblastoma. Cancer Manag Res 2010, 2:97-104.
9. Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Dowell JM, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Wagner M, et al.: Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 2007, 13:1253-9. 10.1158/1078-0432.CCR-06-2309
10. Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, Colman H, Chakravarti A, Pugh S, Won M, et al.: A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 2014, 370:699-708. 10.1056/NEJMoa1308573
11. De Braganca KC, Janjigian YY, Azzoli CG, Kris MG, Pietanza MC, Nolan CP, Omuro AM, Holodny AI, Lassman AB: Efficacy and safety of bevacizumab in active brain metastases from non-small cell lung cancer. J Neurooncol 2010, 100:443-7. 10.1007/s11060-010-0200-2
12. Socinski MA, Langer CJ, Huang JE, Kolb MM, Compton P, Wang L, Akerley W: Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases. J Clin Oncol 2009, 27:5255-61. 10.1200/JCO.2009.22.0616
13. Zustovich F, Ferro A, Lombardi G, Zagonel V, Fiduccia P, Farina P: Bevacizumab as front-line treatment of brain metastases from solid tumors: a case series. Anticancer Res 2013, 33:4061-5.
14. Pope WB, Young JR, Ellingson BM: Advances in MRI assessment of gliomas and response to anti-VEGF therapy. Curr Neurol Neurosci Rep 2011, 11:336-44. 10.1007/s11910-011-0179-x
15. Abbas Z, Gras V, Möllenhoff K, Keil F, Oros-Peusquens AM, Shah NJ: Analysis of proton-density bias corrections based on T1 measurement for robust quantification of water content in the brain at 3 Tesla. Magn Reson Med 2014, 72:1735-45. 10.1002/mrm.25086
16. Kamman RL, Go KG, Brouwer W, Berendsen HJ: Nuclear magnetic resonance relaxation in experimental brain edema: effects of water concentration, proteinconcentration, and temperature. Magn Reson Med 1988, 6:265-74. 10.1002/mrm.1910060304
17. Gahramanov S, Muldoon LL, Li X, Neuwelt EA: Improved perfusion MRI assessment of intracerebral tumor blood volume and antiangiogenic therapy efficacy in a rat model using ferumoxytol. Radiology 2011, 261:796-804. 10.1148/radiol.11103503
18. Hu LS, Baxter LC, Smith KA, Feuerstein BG, Karis JP, Eschbacher JM, Coons SW, Nakaji P, Yeh RF, Debbins J, Heiserman JE: Relative cerebral blood volume values to differentiate high-grade glioma recurrence from posttreatment radiation effect: direct correlation between image-guided tissue histopathology and localized dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging measurements. AJNR Am J Neuroradiol 2009, 30:552-8. 10.3174/ajnr.A1377
19. Li X, Rooney WD, Várallyay CG, Gahramanov S, Muldoon LL, Goodman JA, Tagge IJ, Selzer AH, Pike MM, Neuwelt EA, Springer CSJ: Dynamic-contrast-enhanced-MRI with extravasating contrast reagent: rat cerebral glioma blood volume determination. J Magn Reson 2010, 206:190-9. 10.1016/j.jmr.2010.07.004
20. Roberts HC, Roberts TP, Brasch RC, Dillon WP: Quantitative measurement of microvascular permeability in human brain tumors achieved using dynamic contrast-enhanced MR imaging: correlation with histologic grade. AJNR Am J Neuroradiol 2000, 21:891-9.
21. Tofts PS, Brix G, Buckley DL, Evelhoch JL, Henderson E, Knopp MV, Larsson HB, Lee TY, Mayr NA, Parker GJ, et al.: Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 1999, 10:223-32. 10.1002/(SICI)1522-2586(199909)10:3<223::AID-JMRI2>3.0.CO;2-S
22. Thompson EM, Frenkel EP, Neuwelt EA: The paradoxical effect of bevacizumab in the therapy of malignant gliomas. Neurology 2011, 76:87-93. 10.1212/WNL.0b013e318204a3af
23. Varallyay CG, Nesbit E, Fu R, Gahramanov S, Moloney B, Earl E, Muldoon LL, Li X, Rooney WD, Neuwelt EA: High-resolution steady-state cerebral blood volume maps in patients with central nervous system neoplasms using ferumoxytol, a superparamagnetic iron oxide nanoparticle. J Cereb Blood Flow Metab 2013, 33:780-6. 10.1038/jcbfm.2013.36
24. Fine HA: Bevacizumab in glioblastoma-still much to learn. N Engl J Med 2014, 370:764-5. 10.1056/NEJMe1313309
25. Hein M, Graver S: Tumor cell response to bevacizumab single agent therapy in vitro. Cancer Cell Int 2013, 13:94. 10.1186/1475-2867-13-94
26. Fokas E, Steinbach JP, Rodel C: Biology of brain metastases and novel targeted therapies: time to translate the research. Biochim Biophys Acta 1835, 2013:61-75.
27. Kodack DP, Chung E, Yamashita H, Incio J, Duyverman AM, Song Y, Farrar CT, Huang Y, Ager E, Kamoun W, et al.: Combined targeting of HER2 and VEGFR2 for effective treatment of HER2-amplified breast cancer brain metastases. Proc Natl Acad Sci U S A 2012, 109:E3119-3127. 10.1073/pnas.1216078109
28. Muldoon LL, Gahramanov S, Li X, Marshall DJ, Kraemer DF, Neuwelt EA: Dynamic magnetic resonance imaging assessment of vascular targeting agent effects in rat intracerebral tumor models. Neuro Oncol 2011, 13:51-60. 10.1093/neuonc/noq150
29. JuanYin J, Tracy K, Zhang L, Munasinghe J, Shapiro E, Koretsky A, Kelly K: Noninvasive imaging of the functional effects of anti-VEGF therapy on tumor cell extravasation and regional blood volume in an experimental brain metastasis model. Clin Exp Metastasis 2009, 26:403-414. 10.1007/s10585-009-9238-y
30. Varallyay CG, Muldoon LL, Gahramanov S, Wu YJ, Goodman JA, Li X, Pike MM, Neuwelt EA: Dynamic MRI using iron oxide nanoparticles to assess early vascular effects of antiangiogenic versus corticosteroid treatment in a glioma model. J Cereb Blood Flow Metab 2009, 29:853-60. 10.1038/jcbfm.2008.162
31. Vecht CJ, Hovestadt A, Verbiest HB, van Vliet JJ, van Putten WL: Dose-effect relationship of dexamethasone on Karnofsky performance in metastatic brain tumors: a randomized study of doses of 4, 8, and 16 mg per day. Neurology 1994, 44:675-80. 10.1212/WNL.44.4.675
32. McSheehy PMJ, Weidensteiner C, Cannet C, Ferretti S, Laurent D, Ruetz S, Stumm M, Allegrini PR: Quantified tumor t1 is a generic early-response imaging biomarker for chemotherapy reflecting cell viability. Clin Cancer Res 2010, 16:212-25. 10.1158/1078-0432.CCR-09-0686
33. Jokivarsi KT, Niskanen JP, Michaeli S, Gröhn HI, Garwood M, Kauppinen RA, Gröhn OH: Quantitative assessment of water pools by T 1 rho and T 2 rho MRI in acute cerebral ischemia of the rat. J Cereb Blood Flow Metab 2009, 29:206-16. 10.1038/jcbfm.2008.113
34. Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, Jain RK: Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 2004, 64:3731-6. 10.1158/0008-5472.CAN-04-0074
35. Kienast Y, von Baumgarten L, Fuhrmann M, Klinker WEF, Goldbrunner R, Herms J, Winkler F: Real-time imaging reveals the single steps of brain metastasis formation. Nature Med 2010, 16:116-23. 10.1038/nm.2072
36. Lockman PR, Mittapalli RK, Taskar KS, Rudraraju V, Gril B, Bohn KA, Adkins CE, Roberts A, Thorsheim HR, Gaasch JA, et al.: Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer. Clin Cancer Res 2010, 16:5664-78. 10.1158/1078-0432.CCR-10-1564
37. Claes A, Wesseling P, Jeuken J, Maass C, Heerschap A, Leenders WP: Antiangiogenic compounds interfere with chemotherapy of brain tumors due to vessel normalization. Mol Cancer Ther 2008, 7:71-8.
38. Brandsma D, van den Bent MJ: Pseudoprogression and pseudoresponse in the treatment of gliomas. Curr Opin Neurol 2009, 22:633-8. 10.1097/WCO.0b013e328332363e